Alzamend Neuro Launches Phase II Trials Amidst Stock Surge
By ATTN Desk · Editorial oversight: Sean Han
ALZAMEND NEURO INC (ALZN)
1. Introduction to the Company
Alzamend Neuro Inc. is a clinical-stage biopharmaceutical company (NASDAQ: ALZN) headquartered in Atlanta, Georgia. Founded in 2016 and incorporated in Delaware, the company focuses on developing treatments for:
- Alzheimer’s disease (AD)
- Bipolar disorder
- Major depressive disorder (MDD)
- Post-traumatic stress disorder (PTSD)
The company's mission is to develop therapies for the estimated 43 million Americans affected by these conditions.
2. Corporate Structure and Experience
- Public Company: Ticker ALZN, listed on the NASDAQ
- Employees: 2–10 (LinkedIn)
- Headquarters: 3480 Peachtree Road NE, Suite 103, Atlanta, GA 30326
- Key Collaborations:
- Massachusetts General Hospital (Phase II clinical trials)
- QMENTA (neuroimaging support for clinical trials)
- Licensing: Exclusive, royalty-bearing worldwide licenses from the University of South Florida Research Foundation
3. Recent Developments and News
- May 8, 2025: Filed Form 8-K (Items 5.03, 7.01, 9.01) reporting amendments to governance documents and Regulation FD disclosure.
- April 25, 2025: Filed Form 8-K (Items 5.07, 9.01) updating corporate events.
- April 9, 2025: Filed Prospectus (Rule 424(b)(3)) for the resale of 75,775,110 shares by Orchid Finance LLC; as of April 8, 2025, common stock price was $0.8803.
- March 2025: Initiated the first Phase II head-to-head study of AL001 (“Lithium in Brain”) in healthy subjects to compare lithium blood and brain pharmacokinetics versus marketed lithium carbonate.
- May 2025: Dosed the first patient in the AL001 Phase II trial at Massachusetts General Hospital, with support from QMENTA’s neuroimaging platform.
4. Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (May 29, 2025) | $7.9998 (+140.96%) |
| Volume (May 29, 2025) | 12,345,400 |
| Market Cap (intraday, Yahoo) | $2.43 million |
| Price/Book (mrq) | 0.71 |
| Net Income (ttm) | –$4.23 million |
| Total Cash (mrq) | $3.36 million |
| EPS (ttm) | –1,210.59 |
- Cash Runway: With $3.36 million in cash against a net loss of $4.23 million (ttm), the company may require additional financing to support ongoing Phase II studies.
- Strategic Focus:
- AL001 (LISPRO®): Patented ionic cocrystal delivering lithium, proline, and salicylate. Phase I/II data in AD patients suggested bioequivalence to lithium carbonate with potentially improved pharmacokinetics. Five Phase II studies (AD, bipolar, MDD, PTSD, healthy subjects) planned to commence in Q2 2025.
- ALZN002 (E22W): Autologous dendritic-cell vaccine targeting amyloid clearance. Received FDA “Study May Proceed” for Phase I/IIA in October 2022; trial initiated in March 2023.
5. Market Position and Industry Context
- Industry: Biotechnology research, focusing on neurodegenerative and psychiatric disorders.
- Unmet Need:
- Over 43 million Americans experience cognitive and mood disorders.
- Limited disease-modifying treatments exist for AD, MDD, and PTSD.
- Competitive Landscape: The company faces competition from larger biopharmaceutical firms developing a range of therapeutic approaches. Alzamend’s lithium-based and cell-based vaccine technologies provide distinct mechanisms of action.
- Partnership Leverage: Collaborating with research institutions and AI imaging providers is intended to accelerate trial timelines and enhance data quality.
tl;dr
- On May 29, 2025, ALZN closed at $7.9998, up 140.96% on 12.3 million shares traded.
- Phase II “Lithium in Brain” study of AL001 began in Q2 2025 at Massachusetts General Hospital, supported by QMENTA’s neuroimaging technology.
- Five head-to-head Phase II trials across AD, bipolar disorder, MDD, and PTSD are set to begin in Q2 2025.
- Cash reserve of $3.36 million compared to a $4.23 million annual net loss indicates potential near-term financing needs.
- The ALZN002 Phase I/IIA immunotherapy trial for Alzheimer’s dementia is ongoing, following FDA clearance since March 2023.